Equillium Stock
Equillium, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Bruce D. Steel
- Employees
- 14
- Market cap
- $75 M
- IPO
- 12/10/2018
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a…
Equillium stock: price history
1D
-9.8%
1W
-15.6%
1M
-36.0%
6M
-42.0%
YTD
-23.2%
1Y
-3.3%
2Y
+8.2%
5Y
-79.9%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~10% stronger price swings than usual
Ask the agents about Equillium
Analyst assessment of Equillium
PRICE TARGET LOW
US$5.00
CONSENSUS
US$6.25
MEDIAN
US$6.50
PRICE TARGET HIGH
US$7.00
0
STRONG BUY
11
BUY
1
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 04/09/2026
Equillium stock metrics
P/E
-4.64
P/B
2.38
EV/EBITDA
-1.03
RETURN ON EQUITY
-8.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
58.3%
FLOAT SHARES
36,965,010
AVG. DAILY VOLUME (30D)
659,983
Insider transactions (SEC)
Connelly Stephen
Connelly Stephen
Zedelmayer Christine
Zedelmayer Christine
Zedelmayer Christine
Institutional holders
Comparable stocks
Frequently asked questions about Equillium stock
What does Equillium do?
Equillium, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Bruce D. Steel, the company employs around 14 people.
The IPO was on 12/10/2018; the stock trades on NASDAQ under the ticker EQ.
What do analysts say about Equillium stock?
12 analysts rate the stock, the consensus is Buy (as of 04/09/2026).
The average price target is US$6.25, ranging from US$5.00 to US$7.00, with a median of US$6.50.
This is an external assessment, not a statement by Market Jury.
When does Equillium report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 10% stronger than usual.
Does Equillium pay a dividend?
No, Equillium currently does not pay a dividend.
Which stocks are comparable to Equillium?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Equillium stock analyzed?
Clicking "Analyze stock" lets five strategies assess Equillium against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.